Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Maëlle Duffey Clear advanced filters

  • Current antimalarials often fail to target mature stage V gametocytes. To aid antimalarial drug discovery, the authors present a preclinical malaria transmission-blocking drug research platform, using engineered parasites, that facilitates the screening for gametocytocidal compounds in vitro and the evaluation of transmission-blocking drug activity in vivo.

    • Nicolas M. B. Brancucci
    • Christin Gumpp
    • Till S. Voss
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-21

  • Severe malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model.

    • Stefano Pegoraro
    • Maëlle Duffey
    • Michael Lanzer
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-17

  • The rise of drug resistance presents a significant challenge in the treatment of infectious diseases. This Review summarizes the status and mechanisms of drug resistance in malaria, human immunodeficiency virus (HIV) infection and tuberculosis, and explores strategies to address resistance that could be incorporated into drug development across these disease areas.

    • Maëlle Duffey
    • Robert W. Shafer
    • Didier Leroy
    Reviews
    Nature Reviews Drug Discovery
    Volume: 23, P: 461-479

  • New classes of antibiotic with activity against Gram-negative bacteria that are resistant to existing drugs are urgently needed, but have been very challenging to identify. This Review describes promising but as-yet-unrealized targets for antibacterial drugs against Gram-negative bacteria and highlights lessons learned from past drug discovery programmes.

    • Ursula Theuretzbacher
    • Benjamin Blasco
    • Laura J. V. Piddock
    Reviews
    Nature Reviews Drug Discovery
    Volume: 22, P: 957-975